ACCRUFER™ (ferric maltol) [prescribing information]. London, UK: Shield Therapeutics; Approved 2019.
Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683-690.
Feraheme^® (ferumoxytol injection) [prescribing information]. Waltham, MA: AMAG Pharmaceuticals, Inc.; Revised February 2018.
Ferrlecit^® (sodium ferric gluconate complex in sucrose injection) [prescribing information]. Bridgewater, NJ: Sanofi-aventis US, LLC; Revised September 2019.
Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579-588.
Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299-1307.
Hou JK, Gasche C, Drazin NZ, et al. Assessment of gaps in care and the development of a care pathway for anemia in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:35-43.
INJECTAFER^® (ferric carboxymaltose injection) [prescribing information]. Shirley, NY: American Regent, Inc.; Revised April 2018.
Mücke V, Mücke MM, Raine T, et al. Diagnosis and treatment of anemia in patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30:15-22.
Murawska N, Fabisiak A, Fichna J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment. Inflamm Bowel Dis. 2016;22:1198-1208.
Nielsen OH, Ainsworth M, Coskun M, et al. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine (Baltimore). 2015;94:e963.
Niepel D, Klag T, Malek NP, et al. Practical guidance for the management of iron deficiency anemia in patients with inflammatory bowel disease. Ther Adv Gastroenterol. 2018;11:1-16.
Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44:259-270.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Jason K. Hou, MD

Associate Professor
Medicine and Gastroenterology
Baylor College of Medicine
Houston, Texas

Disclosures

Disclosure: Jason K. Hou, MD, MS, FACG, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Janssen Pharmaceuticals; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Abbvie Inc.; Janssen Pharmaceuticals; Pfizer Inc.
Received grants for clinical research from: Abbvie Inc.; American Regent; Boehringher Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Pfizer Inc.; Redhill Biopharma Ltd.; Shield Therapeutics

Julie Weatherly, RN, MSN, ANP-C

Nurse Practitioner
Michael E. DeBakey VA Medical Center
Houston, Texas

Disclosures

Disclosure: Julie Weatherly, RN, MSN, ANP-C, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie Inc.; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Abbvie Inc.; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

Charles P. Vega, MD

Clinical Professor of Family Medicine
University of California, Irvine,
School of Medicine
Irvine, California

Disclosures

Disclosure: Charles P. Vega, MD, FAFFP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech Inc.; GlaxoSmithKline

Editors

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Anita A. Galdieri, PharmD, RPh

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC / CE

Improving Quality of Care in Patients With Iron Deficiency Anemia and Inflammatory Bowel Disease

Authors: Jason K. Hou, MD; Julie Weatherly, RN, MSN, ANP-C; Charles P. Vega, MD
CME / ABIM MOC / CE Released: 11/27/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/27/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians, hematology/oncology specialists, and nurses.

The goal of this activity is to improve clinicians' knowledge and competence regarding the diagnosis and management of iron deficiency anemia in patients with inflammatory bowel disease (IBD)

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Causes and clinical manifestations of iron deficiency
- Team-based roles in iron deficiency anemia (IDA) recognition and treatment
- Burden and impact of IDA on a patient with inflammatory bowel disease (IBD)
Have greater competence related to
- Diagnostic evaluation for suspected IDA
Demonstrate greater confidence in their ability to
- Treat patients with IBD who have IDA

Disclosures

Faculty

Jason K. Hou, MD

Associate Professor
Medicine and Gastroenterology
Baylor College of Medicine
Houston, Texas

Disclosures

Disclosure: Jason K. Hou, MD, MS, FACG, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Janssen Pharmaceuticals; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Abbvie Inc.; Janssen Pharmaceuticals; Pfizer Inc.
Received grants for clinical research from: Abbvie Inc.; American Regent; Boehringher Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Pfizer Inc.; Redhill Biopharma Ltd.; Shield Therapeutics

Julie Weatherly, RN, MSN, ANP-C

Nurse Practitioner
Michael E. DeBakey VA Medical Center
Houston, Texas

Disclosures

Disclosure: Julie Weatherly, RN, MSN, ANP-C, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie Inc.; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Abbvie Inc.; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

Charles P. Vega, MD

Clinical Professor of Family Medicine
University of California, Irvine,
School of Medicine
Irvine, California

Disclosures

Disclosure: Charles P. Vega, MD, FAFFP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech Inc.; GlaxoSmithKline

Editors

Roderick Smith, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships.

Anita A. Galdieri, PharmD, RPh

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Gastroenterology

CME / ABIM MOC / CE

Improving Quality of Care in Patients With Iron Deficiency Anemia and Inflammatory Bowel Disease

Authors: Jason K. Hou, MD; Julie Weatherly, RN, MSN, ANP-C; Charles P. Vega, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 11/27/2019

Valid for credit through: 11/27/2020

processing....

Assessment Survey

Before you begin, please answer the questions in this brief survey.

Page 1 of 2

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Jason K. Hou, MD

Julie Weatherly, RN, MSN, ANP-C

Charles P. Vega, MD

Editors

Roderick Smith, MS

Anita A. Galdieri, PharmD, RPh

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

CME / ABIM MOC / CE

Improving Quality of Care in Patients With Iron Deficiency Anemia and Inflammatory Bowel Disease

Target Audience and Goal Statement

Disclosures

Faculty

Jason K. Hou, MD

Julie Weatherly, RN, MSN, ANP-C

Charles P. Vega, MD

Editors

Roderick Smith, MS

Anita A. Galdieri, PharmD, RPh

CME, CE Reviewer / Nurse Planner

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Improving Quality of Care in Patients With Iron Deficiency Anemia and Inflammatory Bowel Disease

Assessment Survey